Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences (Nasdaq: PCRX) reported third quarter 2021 financial results, achieving total revenues of $127.7 million, compared to $117.5 million in Q3 2020. The company recorded a GAAP net income of $17.7 million ($0.40 per share) and adjusted EBITDA of $48.1 million, up from $34.2 million a year prior. The positive trajectory is bolstered by strong EXPAREL sales, reaching $121.9 million. A proposed acquisition of Flexion Therapeutics aims to enhance growth efforts. Pacira's financial outlook remains bullish while navigating ongoing challenges from the COVID-19 pandemic.
Pacira BioSciences (Nasdaq: PCRX) has received Notice of Allowance from the USPTO for a U.S. Patent Application related to the chemical composition of EXPAREL (bupivacaine liposome injectable suspension) and a novel manufacturing process. Upon issuance, these patents will be eligible for listing in the FDA Orange Book, extending patent protection until January 22, 2041. This move enhances the company's intellectual property strategy, securing barriers against competition. CEO Dave Stack emphasized confidence in EXPAREL's market leadership across various medical procedures.
Pacira BioSciences, Inc. (NASDAQ:PCRX) is set to release its third quarter financial results on November 3, 2021, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss the results. Participants can join the call by dialing the provided numbers or accessing the webcast via the Pacira investor website. Notably, Pacira emphasizes its leadership in non-opioid pain management, particularly with its long-acting analgesic EXPAREL® and the iovera°® cryoanalgesia system, highlighting its commitment to improving patient outcomes.
Pacira BioSciences (Nasdaq: PCRX) has announced its acquisition of Flexion Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) worth up to $8.00 per share, subject to certain milestones. This acquisition adds ZILRETTA, a non-opioid therapy for osteoarthritis knee pain, to Pacira's portfolio, enhancing its commitment to non-opioid pain management. The deal is expected to be accretive to earnings in 2022 and provides significant synergies. Pacira plans to fund the transaction from existing cash resources and expects it to close in Q4 2021, pending regulatory approvals.
TAMPA, Fla., Oct. 08, 2021 – Pacira BioSciences (NASDAQ: PCRX) announces an Investor Day on October 15, 2021, from 8:00 AM to 12:00 PM ET, at its Innovation and Training Center in Tampa. Key Opinion Leaders and the executive team will discuss updates on the company's commercial products and pipeline opportunities. Attendance is limited and requires advance registration. A live webcast and archived replay will be available on PaciraInvestorDay.com.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has received a Paragraph IV Certification Notice Letter from eVenus Pharmaceutical Laboratories regarding a generic version of EXPAREL (bupivacaine liposome injectable suspension). eVenus alleges the corresponding patent is invalid. Pacira is poised to defend its patent rights and has 45 days to initiate a lawsuit. The company possesses additional patents set to extend EXPAREL's market exclusivity into the 2040s, contributing to its competitive position in non-opioid pain management.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has successfully completed process validation for its EXPAREL product, marking a key milestone in increasing its manufacturing capacity. The new 200-liter production suite in Swindon, England, developed in partnership with Thermo Fisher Scientific, is operational, with sales expected to begin by year-end 2021. This expansion aims to achieve gross margins exceeding 85 percent by 2024. Additionally, a new Orange Book-listed patent extends EXPAREL's market exclusivity to January 2041.
ImmuneID, Inc. has appointed
Pacira BioSciences, Inc. (Nasdaq: PCRX) announced the publication of full results from its Phase 3 PLAY study of EXPAREL in the Journal of Clinical Anesthesia. The study involved 98 pediatric patients undergoing spinal or cardiac surgeries and demonstrated a favorable safety and pharmacokinetic profile, comparable to traditional bupivacaine. Key findings include no serious adverse events and well-tolerated dosing in all age groups. The results support the FDA approval of EXPAREL for pediatric patients aged 6 and older, reinforcing its role as a non-opioid pain management solution.
Pacira BioSciences (Nasdaq: PCRX) reported a 15% increase in EXPAREL net product sales, totaling $41.4 million for August 2021, up from $36.1 million in the previous year. The utilization of EXPAREL, which has treated over nine million patients, is growing despite challenges in the elective surgery market due to the pandemic. The company maintains a positive outlook, expecting annual growth in the high teens and operating margins exceeding 50%. They continue to provide monthly sales updates amid ongoing uncertainties related to COVID-19.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
